{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T14:35:03Z","timestamp":1718462103830},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2014,4,7]],"date-time":"2014-04-07T00:00:00Z","timestamp":1396828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Italian Ministry of Health","award":["MERIT RBNE08NKH7","PO FESR 2007\/2013"],"award-info":[{"award-number":["MERIT RBNE08NKH7","PO FESR 2007\/2013"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Reduced estimated glomerular filtration rate (eGFR) has been associated with increased venous thromboembolism (VTE) risk in the general population. VTE incidence significantly increases in cancer patients, especially those undergoing chemotherapy. Despite the evidence that a substantial number of cancer patients have unrecognized renal impairment, as indicated by reduced eGFR in the presence of serum creatinine levels within the reference value, chemotherapy dosage is routinely adjusted for serum creatinine values. Among chemotherapies, platinum-based regimens are associated with the highest rates of VTE. A cohort study was designed to assess the value of pretreatment eGFR in the risk prediction of a first VTE episode in cancer outpatients without previous history of VTE who were scheduled for platinum-based chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>Serum creatinine and eGFR were evaluated before the start of standard platinum-based chemotherapy in a cohort of 322 consecutive patients with primary or relapsing\/recurrent solid cancers, representative of a general practice population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Patients who experienced a first VTE episode in the course of chemotherapy had lower mean eGFR values compared with patients who remained VTE free. Multivariate Cox analysis demonstrated that eGFR had an independent value for risk prediction of a first VTE episode during treatment, with a 3.15 hazard ratio. Indeed, 14% of patients with reduced eGFR had VTE over 1-year follow-up compared with 6% of patients with normal eGFR values.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>The results suggest that reductions in eGFR, even in the presence of normal serum creatinine, are associated with an increased VTE risk in cancer outpatients undergoing platinum-based chemotherapy regimens. Determining eGFR before chemotherapy could represent a simple predictor of VTE, at no additional cost to health care systems.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2013-0339","type":"journal-article","created":{"date-parts":[[2014,4,8]],"date-time":"2014-04-08T06:06:09Z","timestamp":1396937169000},"page":"562-567","source":"Crossref","is-referenced-by-count":7,"title":["Estimated Glomerular Filtration Rate Is an Easy Predictor of Venous Thromboembolism in Cancer Patients Undergoing Platinum-Based Chemotherapy"],"prefix":"10.1093","volume":"19","author":[{"given":"Patrizia","family":"Ferroni","sequence":"first","affiliation":[{"name":"Biomarker Discovery and Advanced Technologies (BioDAT) Laboratory, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana\u2014Research Center, Rome, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorella","family":"Guadagni","sequence":"additional","affiliation":[{"name":"Biomarker Discovery and Advanced Technologies (BioDAT) Laboratory, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Pisana\u2014Research Center, Rome, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Laudisi","sequence":"additional","affiliation":[{"name":"Department of System Medicine, Medical Oncology, Tor Vergata Clinical Center, University of Rome \u201cTor Vergata,\u201d Rome, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Vergati","sequence":"additional","affiliation":[{"name":"Department of System Medicine, Medical Oncology, Tor Vergata Clinical Center, University of Rome \u201cTor Vergata,\u201d Rome, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Riondino","sequence":"additional","affiliation":[{"name":"Department of System Medicine, Medical Oncology, Tor Vergata Clinical Center, University of Rome \u201cTor Vergata,\u201d Rome, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology, Department of Surgical and Oncology Sciences, University of Palermo, Palermo, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Dav\u00ec","sequence":"additional","affiliation":[{"name":"Internal Medicine and Center of Excellence on Aging, \u201cG. d'Annunzio\u201d University Foundation, Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Roselli","sequence":"additional","affiliation":[{"name":"Department of System Medicine, Medical Oncology, Tor Vergata Clinical Center, University of Rome \u201cTor Vergata,\u201d Rome, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,4,7]]},"reference":[{"key":"2021122309082507900_B1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2007.02450.x","article-title":"Incidence and mortality of venous thrombosis: A population-based study","volume":"5","author":"Naess","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2021122309082507900_B2","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases","volume":"49","author":"Walker","year":"2013","journal-title":"Eur J Cancer"},{"key":"2021122309082507900_B3","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States","volume":"119","author":"Khorana","year":"2013","journal-title":"Cancer"},{"key":"2021122309082507900_B4","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1001\/jama.2009.565","article-title":"Microalbuminuria and risk of venous thromboembolism","volume":"301","author":"Mahmoodi","year":"2009","journal-title":"JAMA"},{"key":"2021122309082507900_B5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1681\/ASN.2007030308","article-title":"Chronic kidney disease increases risk for venous thromboembolism","volume":"19","author":"Wattanakit","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2021122309082507900_B6","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1093\/ndt\/gfq179","article-title":"Chronic kidney disease and venous thromboembolism: A prospective study","volume":"25","author":"Folsom","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2021122309082507900_B7","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1053\/j.ajkd.2011.06.021","article-title":"Venous thromboembolism in patients with reduced estimated GFR: A population-based perspective","volume":"58","author":"Parikh","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2021122309082507900_B8","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1161\/CIRCULATIONAHA.112.113944","article-title":"Association of mild to moderate chronic kidney disease with venous thromboembolism: Pooled analysis of five prospective general population cohorts","volume":"126","author":"Mahmoodi","year":"2012","journal-title":"Circulation"},{"key":"2021122309082507900_B9","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/CAD.0b013e328355dd8a","article-title":"Unrecognized renal insufficiency and chemotherapy-associated adverse effects among breast cancer patients","volume":"23","author":"Lotan","year":"2012","journal-title":"Anticancer Drugs"},{"key":"2021122309082507900_B10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/rej.2010.1141","article-title":"Platinum-based compounds and risk for cardiovascular toxicity in the elderly: Role of the antioxidants in chemoprevention","volume":"14","author":"Ferroni","year":"2011","journal-title":"Rejuvenation Res"},{"key":"2021122309082507900_B11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-9-179","article-title":"Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: Results of a retrospective analysis of the PROTECHT study","volume":"9","author":"Barni","year":"2011","journal-title":"J Transl Med"},{"key":"2021122309082507900_B12","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/ijc.28104","article-title":"Impact of chemotherapy on activated protein C-dependent thrombin generation\u2014association with VTE occurrence","volume":"133","author":"Roselli","year":"2013","journal-title":"Int J Cancer"},{"key":"2021122309082507900_B13","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"2021122309082507900_B14","volume-title":"WHO draft guidelines for adverse event reporting and learning systems: From information to action","author":"World Alliance for Patient Safety"},{"key":"2021122309082507900_B15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"2021122309082507900_B16","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2021122309082507900_B17","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122309082507900_B18","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1002\/cncr.24665","article-title":"Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer","volume":"115","author":"Lyman","year":"2009","journal-title":"Cancer"},{"key":"2021122309082507900_B19","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.21.7752","article-title":"D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study","volume":"27","author":"Ay","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309082507900_B20","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"2021122309082507900_B21","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1160\/TH10-11-0757","article-title":"An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients","volume":"105","author":"Ferroni","year":"2011","journal-title":"Thromb Haemost"},{"key":"2021122309082507900_B22","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2010.32.8294","article-title":"Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: Results from the Vienna Cancer and Thrombosis Study","volume":"29","author":"Ay","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122309082507900_B23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1160\/TH12-02-0099","article-title":"Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study","volume":"108","author":"Van Doormaal","year":"2012","journal-title":"Thromb Haemost"},{"key":"2021122309082507900_B24","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.12163","article-title":"Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: A randomized-controlled phase II trial (the Microtec study)","volume":"160","author":"Zwicker","year":"2013","journal-title":"Br J Haematol"},{"key":"2021122309082507900_B25","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Lyman","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309082507900_B26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: The Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern Emerg Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2013-0339","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2013-0339","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/5\/562\/41862625\/oncolo_19_5_562.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/5\/562\/41862625\/oncolo_19_5_562.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T02:08:40Z","timestamp":1640311720000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/19\/5\/562\/6399321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,7]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,4,7]]},"published-print":{"date-parts":[[2014,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2013-0339","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,5,1]]},"published":{"date-parts":[[2014,4,7]]}}}